Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmacytoid dendritic cell | 20 studies | 55% ± 15% | |
| plasma cell | 18 studies | 27% ± 10% | |
| plasmablast | 9 studies | 33% ± 15% | |
| dendritic cell | 8 studies | 32% ± 7% | |
| IgA plasma cell | 6 studies | 25% ± 7% | |
| naive B cell | 5 studies | 20% ± 3% | |
| precursor B cell | 5 studies | 36% ± 15% | |
| B cell | 3 studies | 16% ± 1% | |
| regulatory T cell | 3 studies | 19% ± 2% | |
| IgG plasma cell | 3 studies | 23% ± 1% |
Insufficient scRNA-seq data for expression of IRF4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 98% | 664.08 | 565 / 578 | 74% | 6.51 | 860 / 1155 |
| skin | 74% | 462.60 | 1342 / 1809 | 94% | 68.72 | 444 / 472 |
| breast | 97% | 975.22 | 447 / 459 | 48% | 3.97 | 539 / 1118 |
| stomach | 72% | 465.98 | 258 / 359 | 56% | 3.83 | 160 / 286 |
| intestine | 62% | 1233.42 | 602 / 966 | 45% | 3.26 | 236 / 527 |
| uterus | 58% | 759.61 | 98 / 170 | 42% | 2.57 | 195 / 459 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 120.83 | 29 / 29 |
| spleen | 100% | 4844.17 | 241 / 241 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 98% | 91.10 | 78 / 80 |
| adipose | 94% | 686.13 | 1131 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 92% | 13402.26 | 857 / 929 | 0% | 0 | 0 / 0 |
| bladder | 52% | 254.67 | 11 / 21 | 38% | 2.18 | 193 / 504 |
| thymus | 40% | 275.18 | 262 / 653 | 45% | 3.82 | 272 / 605 |
| esophagus | 34% | 103.56 | 486 / 1445 | 45% | 3.18 | 83 / 183 |
| tonsil | 0% | 0 | 0 / 0 | 73% | 9.99 | 33 / 45 |
| liver | 52% | 344.02 | 117 / 226 | 12% | 0.82 | 47 / 406 |
| ovary | 40% | 128.71 | 72 / 180 | 19% | 1.10 | 82 / 430 |
| kidney | 22% | 115.06 | 20 / 89 | 24% | 1.23 | 216 / 901 |
| pancreas | 3% | 5.10 | 9 / 328 | 40% | 2.55 | 72 / 178 |
| prostate | 31% | 91.68 | 75 / 245 | 9% | 0.43 | 43 / 502 |
| blood vessel | 26% | 78.79 | 350 / 1335 | 0% | 0 | 0 / 0 |
| heart | 24% | 93.41 | 209 / 861 | 0% | 0 | 0 / 0 |
| adrenal gland | 9% | 17.26 | 22 / 258 | 1% | 0.06 | 3 / 230 |
| muscle | 9% | 16.36 | 75 / 803 | 0% | 0 | 0 / 0 |
| brain | 1% | 3.74 | 29 / 2642 | 4% | 0.52 | 25 / 705 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002376 | Biological process | immune system process |
| GO_0032753 | Biological process | positive regulation of interleukin-4 production |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0042832 | Biological process | defense response to protozoan |
| GO_0032736 | Biological process | positive regulation of interleukin-13 production |
| GO_0032733 | Biological process | positive regulation of interleukin-10 production |
| GO_0006338 | Biological process | chromatin remodeling |
| GO_0032743 | Biological process | positive regulation of interleukin-2 production |
| GO_0045622 | Biological process | regulation of T-helper cell differentiation |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0072540 | Biological process | T-helper 17 cell lineage commitment |
| GO_0043011 | Biological process | myeloid dendritic cell differentiation |
| GO_0034122 | Biological process | negative regulation of toll-like receptor signaling pathway |
| GO_0120162 | Biological process | positive regulation of cold-induced thermogenesis |
| GO_0042110 | Biological process | T cell activation |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0000786 | Cellular component | nucleosome |
| GO_0016020 | Cellular component | membrane |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0000785 | Cellular component | chromatin |
| GO_0005634 | Cellular component | nucleus |
| GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
| GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
| GO_0043565 | Molecular function | sequence-specific DNA binding |
| GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
| GO_0003700 | Molecular function | DNA-binding transcription factor activity |
| GO_0003713 | Molecular function | transcription coactivator activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | IRF4 |
| Protein name | Interferon regulatory factor 4 Interferon regulatory factor 4 (IRF-4) (Lymphocyte-specific interferon regulatory factor) (LSIRF) (Multiple myeloma oncogene 1) (NF-EM5) |
| Synonyms | hCG_20902 MUM1 |
| Description | FUNCTION: Transcriptional activator. Binds to the interferon-stimulated response element (ISRE) of the MHC class I promoter. Binds the immunoglobulin lambda light chain enhancer, together with PU.1. Probably plays a role in ISRE-targeted signal transduction mechanisms specific to lymphoid cells. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF4 and activation of genes (By similarity). . |
| Accessions | ENST00000696871.1 [Q15306-2] A0A8Q3WLQ3 F2Z3D5 ENST00000493114.2 ENST00000696873.1 Q15306 ENST00000380956.9 [Q15306-1] ENST00000696872.1 A0A8Q3WLL3 |
